EN
中文
EN
Who We Are
Newsroom
Innovation
Products
Investor Relations
Careers
Contact Us
Information Disclosure
Home
>
Investor Relations
>
Information Disclosure
H Share
THIRD QUARTERLY REPORT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024
NOTICE OF BOARD MEETING
VOLUNTARY ANNOUNCEMENT - RECOMBINANT POLIOMYELITIS VACCINE OBTAINS CLINICAL TRIAL APPROVAL IN INDONESIA
VOLUNTARY ANNOUNCEMENT - GRANT AGREEMENT OF RECOMBINANT POLIOMYELITIS VACCINE AND RELATED COMBINED VACCINE PROJECT
Monthly Return of Equity Issuer on Movements in Securities
INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
Monthly Return of Equity Issuer on Movements in Securities
DISCLOSEABLE TRANSACTION PURCHASE OF STRUCTURED DEPOSIT
VOLUNTARY ANNOUNCEMENT POSITIVE PRELIMINARY PHASE I CLINICAL RESULTS FOR PROTEIN-BASED PNEUMOCOCCAL VACCINE
VOLUNTARY ANNOUNCEMENT HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE, FREEZE-DRIED OBTAINS CLINICAL TRIAL APPROVAL
1
8
9
10
11
12
52
津公网安备12011602300399
